Lawmakers challenge drug company CEO over steep prices for Ozempic and Wegovy
Ozempic and Wegovy are some of the most popular drugs in the country, driven by their remarkable success in treating diabetes and obesity. But the drugs are extremely expensive, and the drugmaker’s CEO appeared on Capitol Hill Tuesday to face questions about why those prices are so high.
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback